New Search

Export article

Tocilizumab for the treatment of severe COVID-19

Karen O’Leary
Published: 13 May 2021
Nature Medicine ; doi:10.1038/d41591-021-00031-7

Abstract: The RECOVERY study shows that anti-IL-6 agent tocilizumab improves outcomes in hypoxic patients with COVID-19. The RECOVERY study shows that anti-IL-6 agent tocilizumab improves outcomes in hypoxic patients with COVID-19.
Keywords: Clinical trials / Infection / SARS-CoV-2

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

Share this article

Click here to see the statistics on "Nature Medicine" .
Back to Top Top